Of all five U.S. Multi Society Task Force recommended tests, FIT-fecal DNA every three years was most preferred test
WEDNESDAY, Sept. 21, 2022 (HealthDay News) — Unscreened adults aged 40 years and older at average risk for colorectal cancer (CRC) prefer fecal immunochemical test (FIT)-fecal DNA every three years, according to a study published online July 20 in Clinical Gastroenterology and Hepatology.
Katherine E. Makaroff, M.D., from Cedars-Sinai Center for Outcomes Research and Education in Los Angeles, and colleagues conducted a conjoint analysis survey among unscreened individuals aged 40 years and older at average risk for CRC to examine the relative importance of screening test attributes in their decision-making. The analyses were stratified among those aged 40 to 49 years and 50 years and older. The conjoint analysis was completed by 1,000 participants (456 aged 40 to 49 years; 544 aged 50 years or older).
The researchers found differences in test preferences between age groups when considering all five U.S. Multi Society Task Force (MSTF) recommended tests; a FIT-fecal DNA every three years was the most preferred test (34.6 percent for those aged 40 to 49 years; 37.3 percent for those aged 50 years and older). Most participants preferred an annual FIT over a colonoscopy every 10 years when considering only the U.S. MSTF tier 1 tests (68.9 percent for 40- to 49-year-olds; 77.4 percent for those aged 50 years and older).
“If we give patients a choice, we may be able to move the needle in trying to improve colorectal cancer screening rates overall, so that more people can get screened, and fewer people develop this preventable cancer,” a coauthor said in a statement.
One author disclosed financial ties to Exact Sciences.
Abstract/Full Text (subscription or payment may be required)
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
Surveillance Colonoscopy at Five Years After Adenoma Removal Noninferior to Three Years
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Gene Mutation Identified That Increases Lung Cancer Risk
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50